Thirty million Americans depend on daily doses of insulin to stay alive.  This small protein hormone is responsible for the regulation of blood sugar, and plays a key role in all aspects of physiology, as well as long-term effects on health. Despite its importance, the vast majority of insulin is produced off shore, leaving it vulnerable to supply chain disruptions that could be hazardous for many Americans. Domestic production is hindered by a variety of barriers, from production to regulatory. Cameron Owen is the CEO and Co-Founder of rBIO, and they are using a specially designed E. coli bacterium that focuses strictly on insulin production. This streamlining of the process around bacteria that commit the majority of resources into insulin production leads to minimizing side reactions and higher yields of the desired product. Making the production process more efficient means that this critical hormone may be produced at a lower price and without fear of supply chain production.Follow rBIO on twitter at @rBio_pharma# COLABRATalking Biotech is brought to you by Colabra – an R&D platform that brings your lab’s world-changing research together in one shared space. Learn more at https://www.colabra.app/# TALKING BIOTECHTwitter: https://twitter.com/talkingbiotechWebsite: https://www.colabra.app/podcasts/talking-biotech/Instagram: https://www.instagram.com/colabrahqThe Talking Biotech podcast is distinct from Dr. Kevin Folta's teaching and research roles at the University of Florida. The views expressed on the show are those of Dr. Folta and his guests, and do not reflect the opinions of the university or Colabra.